SLC5A2 and hydrops fetalis: Given the emerging evidence that sodium–glucose co‐transporter 2 (SGLT2) inhibitors reduce the risk of incident HF,11, 12, 13 a holistic evaluation of the association between the spectrum of LVEF and HF risk in clinical practice is necessary.